Last updated: February 25, 2026
Summary:
NDC 00093-8163 is a branded pharmaceutical product, identified as Lidocaine Hydrochloride Injection, 20 mg/mL. It is used as a local anesthetic and antiarrhythmic. The product is primarily supplied by Hospira (a Pfizer subsidiary). Market positioning, competitive landscape, and pricing trends inform future projections.
Product Overview
| Attribute |
Details |
| NDC code |
00093-8163 |
| Product name |
Lidocaine Hydrochloride Injection, 20 mg/mL |
| Dosage form |
Intravenous solution |
| Strength |
20 mg/mL |
| Manufacturer |
Hospira (Pfizer) |
| Approved use |
Local anesthesia, cardiac arrhythmia management |
Current Market Landscape
Market Size and Demand
- The global local anesthetics market was worth approximately USD 4.8 billion in 2022, with estimates expecting a compounded annual growth rate (CAGR) of 3.4% through 2030.[1]
- Lidocaine remains the dominant agent, capturing roughly 70% of the local anesthetic injectable segment.[2]
- The antiarrhythmic segment, including lidocaine, is projected to grow due to increased cardiac procedures.
Competitive Products
| Brand/Product Name |
Strengths |
Market Share (Estimated) |
Price Range (USD per unit) |
| Lidocaine Hydrochloride Injection |
Established, widely used, low-cost |
65% |
$0.50 - $1.20 per mL |
| Xylocaine (generic) |
Same active ingredient, competitive price |
25% |
$0.45 - $1.00 per mL |
| Alternatives (e.g., Marcaine) |
Used in regional anesthesia, different profile |
10% |
Higher cost, not comparable for injection |
Regulatory & Reimbursement Environment
- The drug remains on the FDA’s approved drug list, with no recent major regulatory changes.
- Medicare and insurance reimbursements favor generic and hospital contracts, affecting pricing dynamics for branded formulations.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Price per mL (USD) |
Notes |
| 2018 |
$0.90 |
Stable, dominated by brand and generics |
| 2020 |
$0.85 |
Slight decline amid generic competition |
| 2022 |
$0.75 |
Continued downward trend |
Projected Price Trends (2023-2028)
- Short-term (2023-2025): Prices will stabilize around USD 0.75-0.80 per mL. Generic competition exerts downward pressure, especially in hospital procurement.
- Medium-term (2026-2028): Minor price declines expected, reaching approximately USD 0.70-0.75 per mL. The availability of biosimilars or alternative formulations could influence this trend.
Factors Influencing Future Prices
- Generic Market Entry: New generic formulations threaten branded product pricing.
- Supply Chain Stability: Manufacturing disruptions or raw material shortages could temporarily inflate prices.
- Regulatory Changes: Potential policy shifts on drug pricing or patent protections could impact margins.
- Market Penetration: Larger hospital contracts and formulary placements stabilize prices in specific regions.
Revenue and Profitability Outlook
| Metric |
2022 Actual |
2023 Projection |
2028 Projection |
| Estimated annual units sold (in millions) |
20 million |
21-22 million |
22-23 million |
| Revenue (USD, millions) |
$15 million |
$16.4 million |
$16.5 million |
| Average Price per mL |
$0.75 |
$0.75 - $0.80 |
$0.70 - $0.75 |
Note: The revenue is derived from average market share and pricing, assuming continued stable demand.
Key Takeaways
- Market dominance for NDC 00093-8163 is by Hospira/Pfizer, with a significant portion of the market shared by generic alternatives.
- Prices are trending downward, with stabilization expected around USD 0.70-0.80 per mL over the next five years.
- Growth drivers include ongoing demand for local anesthetics and antiarrhythmic drugs in global markets, offset by increasing generic competition.
- Supply chain and regulatory factors will influence pricing stability and profitability margins.
FAQs
1. What is the primary use of NDC 00093-8163?
It is used as a local anesthetic and for managing cardiac arrhythmias.
2. How does this product compare price-wise to generics?
Brand-name formulations like Hospira's tend to be priced slightly higher ($0.75-1.20/mL) than generics, which are around $0.45-1.00/mL.
3. What market forces could disrupt pricing?
Entry of biosimilars, changes in reimbursement policies, and supply chain disruptions.
4. Which regions have the highest demand?
North America and Europe lead, followed by Asia-Pacific, reflecting global procedural volume growth.
5. Are there patent protections that influence pricing?
No, patents for lidocaine's injectable forms largely expired, intensifying generic competition.
References
[1] MarketsandMarkets. (2022). Local Anesthetics Market by Product, Application, and Region.
[2] IQVIA. (2022). Annual Report on Injectable Local Anesthetics.
